conivaptan has been researched along with risperidone in 4 studies
| Studies (conivaptan) | Trials (conivaptan) | Recent Studies (post-2010) (conivaptan) | Studies (risperidone) | Trials (risperidone) | Recent Studies (post-2010) (risperidone) |
|---|---|---|---|---|---|
| 188 | 17 | 64 | 6,924 | 1,505 | 2,477 |
| Protein | Taxonomy | conivaptan (IC50) | risperidone (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 4 | Cavia porcellus (domestic guinea pig) | 0.015 | |
| 5-hydroxytryptamine receptor 2C | Rattus norvegicus (Norway rat) | 0.0027 | |
| Alpha-2A adrenergic receptor | Homo sapiens (human) | 0.0097 | |
| Cytochrome P450 2D6 | Homo sapiens (human) | 5.2734 | |
| Angiotensin-converting enzyme | Oryctolagus cuniculus (rabbit) | 4.1901 | |
| D(2) dopamine receptor | Homo sapiens (human) | 0.0167 | |
| 5-hydroxytryptamine receptor 2A | Rattus norvegicus (Norway rat) | 0.0991 | |
| Alpha-2B adrenergic receptor | Homo sapiens (human) | 0.026 | |
| Alpha-2C adrenergic receptor | Homo sapiens (human) | 0.0096 | |
| 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Norway rat) | 0.799 | |
| D(1A) dopamine receptor | Homo sapiens (human) | 0.479 | |
| Histamine H2 receptor | Homo sapiens (human) | 1.483 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 0.01 | |
| 5-hydroxytryptamine receptor 2A | Homo sapiens (human) | 0.0016 | |
| 5-hydroxytryptamine receptor 2C | Homo sapiens (human) | 0.0057 | |
| 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Norway rat) | 0.799 | |
| 5-hydroxytryptamine receptor 2B | Rattus norvegicus (Norway rat) | 0.0027 | |
| 5-hydroxytryptamine receptor 2C | Mus musculus (house mouse) | 0.0015 | |
| Alpha-1A adrenergic receptor | Homo sapiens (human) | 0.0105 | |
| 5-hydroxytryptamine receptor 2A | Mus musculus (house mouse) | 0.0015 | |
| Histamine H1 receptor | Homo sapiens (human) | 0.4515 | |
| D(3) dopamine receptor | Homo sapiens (human) | 0.024 | |
| 5-hydroxytryptamine receptor 2B | Homo sapiens (human) | 0.023 | |
| D(2) dopamine receptor | Mus musculus (house mouse) | 0.023 | |
| D(2) dopamine receptor | Rattus norvegicus (Norway rat) | 0.0154 | |
| 5-hydroxytryptamine receptor 2B | Mus musculus (house mouse) | 0.0015 | |
| Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | 0.6303 | |
| 5-hydroxytryptamine receptor 1A | Mus musculus (house mouse) | 0.43 | |
| Nuclear receptor subfamily 3 group C member 3 | Bos taurus (cattle) | 4.1901 | |
| Multidrug and toxin extrusion protein 1 | Homo sapiens (human) | 1.6 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Mowrey, DD; Sun, T; Tang, P; Tillman, TS; Wells, MM; Xu, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for conivaptan and risperidone
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
3 other study(ies) available for conivaptan and risperidone
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
Topics: Analgesics, Non-Narcotic; Animals; Binding Sites; Cannabinoids; Drug Evaluation, Preclinical; Female; Lipids; Molecular Dynamics Simulation; Molecular Targeted Therapy; Nuclear Magnetic Resonance, Biomolecular; Oocytes; Pain; Protein Conformation; Protein Structure, Tertiary; Receptors, Glycine; Reproducibility of Results; Xenopus laevis | 2015 |